Education
About Us
Working with TipRanks
Follow Us
Amplia Therapeutics Ltd. (AU:ATX)
ASX:ATX
Total Valuation
Amplia Therapeutics has a market cap or net worth of $84.66M. The enterprise value is AU$14.69M.
Market Cap$84.66M
Enterprise ValueAU$14.69M
Share Statistics
Amplia Therapeutics has 513,071,660 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding513,071,660
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Amplia Therapeutics’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -13.18%.
Return on Equity (ROE)-0.31
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-13.18%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee3.78M
Profits Per Employee0.00
Employee Count1
Asset Turnover0.16
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Amplia Therapeutics is ―. Amplia Therapeutics’s PEG ratio is 0.42.
PE Ratio―
PS Ratio5.68
PB Ratio1.02
Price to Fair Value1.02
Price to FCF-3.12
Price to Operating Cash Flow-8.64
PEG Ratio0.42
Income Statement
In the last 12 months, Amplia Therapeutics had revenue of 3.78M and earned -6.57M in profits. Earnings per share was -0.02.
Revenue3.78M
Gross Profit3.57M
Operating Income-6.52M
Pretax Income-6.57M
Net Income-6.57M
EBITDA-6.78M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -6.89M and capital expenditures -2.07K, giving a free cash flow of -6.89M billion.
Operating Cash Flow-6.89M
Free Cash Flow-6.89M
Free Cash Flow per Share-0.01
Dividends & Yields
Amplia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.14
52-Week Price Change5.59%
50-Day Moving Average0.18
200-Day Moving Average0.13
Relative Strength Index (RSI)50.76
Average Volume (3m)1.95M
Important Dates
Amplia Therapeutics upcoming earnings date is Nov 27, 2025, TBA (Confirmed).
Last Earnings DateMay 30, 2025
Next Earnings DateNov 27, 2025
Ex-Dividend Date―
Financial Position
Amplia Therapeutics as a current ratio of 7.91, with Debt / Equity ratio of 0.07%
Current Ratio7.91
Quick Ratio7.91
Debt to Market Cap0.00
Net Debt to EBITDA1.60
Interest Coverage Ratio-116.60
Taxes
In the past 12 months, Amplia Therapeutics has paid -3.77M in taxes.
Income Tax-3.77M
Effective Tax Rate0.57
Enterprise Valuation
Amplia Therapeutics EV to EBITDA ratio is -1.57, with an EV/FCF ratio of -1.55.
EV to Sales2.81
EV to EBITDA-1.57
EV to Free Cash Flow-1.55
EV to Operating Cash Flow-1.55
Balance Sheet
Amplia Therapeutics has $10.86M in cash and marketable securities with $13.89K in debt, giving a net cash position of $10.85M billion.
Cash & Marketable Securities$10.86M
Total Debt$13.89K
Net Cash$10.85M
Net Cash Per Share$0.02
Tangible Book Value Per Share$0.04
Margins
Gross margin is 94.43%, with operating margin of -172.22%, and net profit margin of -173.69%.
Gross Margin94.43%
Operating Margin-172.22%
Pretax Margin-173.69%
Net Profit Margin-173.69%
EBITDA Margin-179.24%
EBIT Margin-179.51%
Analyst Forecast
The average price target for Amplia Therapeutics is $0.42, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$0.42
Price Target Upside136.00% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast4.07%